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Candida albicans fungemia in cancer patients is thought to develop from initial gastrointestinal (GI) colonization with
subsequent translocation into the bloodstream after administration of chemotherapy. It is unclear what components of
the innate immune system are necessary for preventing C. albicans dissemination from the GI tract, but we have
hypothesized that both neutropenia and GI mucosal damage are critical for allowing widespread invasive C. albicans
disease. We investigated these parameters in a mouse model of C. albicans GI colonization that led to systemic spread
after administration of immunosuppression and mucosal damage. After depleting resident GI intestinal flora with
antibiotic treatment and achieving stable GI colonization levels of C. albicans, it was determined that systemic
chemotherapy with cyclophosphamide led to 100% mortality, whereas selective neutrophil depletion, macrophage
depletion, lymphopenia or GI mucosal disruption alone resulted in no mortality. Selective neutrophil depletion
combined with GI mucosal disruption led to disseminated fungal infection and 100% mortality ensued. GI translocation
and dissemination by C. albicans was also dependent on the organism’s ability to transform from the yeast to the
hyphal form. This mouse model of GI colonization and fungemia is useful for studying factors of innate host immunity
needed to prevent invasive C. albicans disease as well as identifying virulence factors that are necessary for fungal GI
colonization and dissemination. The model may also prove valuable for evaluating therapies to control C. albicans
infections.
Citation: Koh AY, Ko ¨hler JR, Coggshall KT, Van Rooijen N, Pier GB (2008) Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 4(2):
e35. doi:10.1371/journal.ppat.0040035
Introduction
Candida albicans is a ubiquitous commensal organism that
can cause serious disseminated infections in cancer patients
[1,2]. Candida spp. are the fourth leading cause of nosocomial
bloodstream infections in the United States, with treatment
costs estimated to be more than $2–$4 billion annually [3] and
with attributable mortality rates estimated to be between
38% to 49% [4]. Among the various invasive fungal infections
reported in cancer patients, candidiasis is the most common
infection (58%–69%) [5–7], and over the past decade, the
incidence of invasive fungal infections in this population has
increased signiﬁcantly [8].
The presumed mechanism for all invasive C. albicans disease
involves initial mucosal surface colonization followed by
invasion into the adjacent tissues and organs. In cancer
patients, C. albicans usually colonizes the gastrointestinal (GI)
t r a c tw i t hs u b s e q u e n tt r a n s l o cation into extraintestinal
organs (i.e., mesenteric lymph nodes, blood stream, liver,
and spleen) in the setting of chemotherapy-induced neutro-
penia and GI mucosal damage [9]. The three primary
mechanisms that promote pathogenic microbial (bacterial
and fungal) translocation in animal models are: 1) disruption
of the normal GI microbiologic equilibrium allowing in-
testinal overgrowth of pathogens, 2) increased permeability
of the intestinal mucosal barrier, and 3) deﬁciencies in the
host immune defenses [10,11]. Not surprisingly, common risk
factors for developing candidemia in human patients include
neutropenia, mucositis, use of broad spectrum antibiotics,
and invasive medical procedures [6,12].
The majority of murine models of disseminated candidiasis
have employed the administration of a chemotherapeutic
agent (e.g., cyclophosphamide) followed by the subsequent
intravenous injection of C. albicans [13,14] or simply the
intravenous injection of high inocula of C. albicans [15,16].
Therefore, a murine model that ﬁrst establishes GI coloniza-
tion followed by translocation and dissemination via dis-
ruptions of select components of the innate host defense
would afford valuable opportunities for studying the details
of C. albicans pathogenesis, as well as delineating the relative
roles of the major immune compartments or the actual
immune mechanisms responsible for killing and/or control-
ling translocating C. albicans [10].
To evaluate normal host factors that must be disrupted to
allow for GI colonization, fungal dissemination and signiﬁ-
cant morbidity or mortality due to candidemia, we have
developed a reproducible mouse model wherein C. albicans GI
colonization is ﬁrst established and subsequent fungal
dissemination is achieved following induction of immuno-
suppression and disruption of mucosal integrity. Both
neutropenia and GI mucosal damage appear to be necessary
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evaluated C. albicans mutants that had varying abilities to
switch between the yeast and the hyphal growth form of C.
albicans and found changes in virulence associated with an
inability to switch to the hyphal phase, indicating the utility
of this animal model for studying different aspects of the
pathogenic process of C. albicans in the setting of GI
colonization and dissemination.
Results
GI Colonization by C. albicans
Wild-type C. albicans strains SC5314 (a strain that has been
frequently used in various C. albicans murine models [17–20])
and CAF2–1 consistently colonized the mouse GI tract at
comparable levels: SC5314 (median ¼ 2.24 3 10
7 cfu/g stool,
ﬁrst quartile ¼ 1.07 3 10
7, third quartile ¼ 3.75 3 10
7) and
CAF2–1 (median¼2.60310
7 cfu/g stool, ﬁrst quartile¼2.283
10
7, third quartile ¼ 3.19 3 10
7; Figure 1). When tested up to
21 d later, there was no signiﬁcant change in fungal
colonization levels of the stool.
Dissemination by C. albicans
Mice that were colonized with C. albicans strains SC5314 and
CAF2–1, as well as non-Candida colonized control mice that
were only decontaminated with antibiotics, were separated
into 17 groups (8 mice/group, with the exception of 4 mice/
group in Rag
 /  mice), treated with immunosuppressive
regimens (Table 1), and the effect on dissemination of the
different methods of immunosuppression determined (Table
2). Mice that were only decontaminated with antibiotics all
survived after administration of immunosuppressive regi-
mens—with the exception of 1 death in the group given mAb
RB6-8C5 plus methotrexate (MTX) (Group 7). All groups that
were colonized with C. albicans strains SC5314 and CAF2–1
then given immunosuppression showed levels of GI coloniza-
tion comparable to those of mice not given immunosuppres-
sion (results shown in Figure 1; data for immunosuppressed
mice not shown). Mice that were only given antibiotic
decontamination and no immunosuppression after coloniza-
tion with C. albicans (Group 1) also all survived.
Chemotherapy. When either Cy alone (Group 2), Cy plus
MTX (Group 3) or mAb RB6-8C5 plus MTX (Group 5) were
administered, fungal dissemination occurred in all mice
associated with a high level of mortality. Interestingly, when
MTX alone (Group 4) was given, 3 of 8 mice in the group
colonized with strain SC5314 and 4 of 8 mice in the group
colonized with strain CAF2–1 died from disseminated disease.
In contrast, when MTX was given concurrently with mAb
RB6-8C5 (Group 5), all mice died following fungal dissem-
ination.
Neutrophil depletion. Mice that were made neutropenic
after a single injection of 200 lg of anti-neutrophil mAb RB6-
8C5 (mAb 3 1) survived (Group 6). Even when given two
additional doses of mAb RB6-8C5 (mAb 3 3; Group 7) and
thus made neutropenic for 15 d, there was no evidence of C.
albicans dissemination in these mice. The four mice that died
in this group only showed evidence of bacterial (e.g.,
Enterobacter spp.), not fungal, dissemination.
Macrophage depletion. By immunohistochemical analysis,
macrophages in both the liver and spleen were reduced after
liposomal clodronate administration (Figure S1). By FACS
analysis, F4/80 and CD11b double-stained macrophages were
reduced in the spleen and bone marrow after liposomal
clodronate administration from 26% to 16% (Figure S2).
Mice given liposomal clodronate (Group 8), clodronate plus
mAb RB6-8C5 (Group 9), or clodronate plus DSS (Group 10)
all survived.
Lack of functional lymphocytes. RAG
 /  mice colonized
with strains SC5314 or CAF2–1 showed no evidence of
dissemination (Group 11)—not even when mAb RB6-8C5
(Group 12), DSS (Group 13), or liposomal clodronate (Group
14) were subsequently administered to different groups of
RAG
 /  mice.
GI mucosal disruption. There was no histologic evidence of
any GI mucosal injury or damage in the ceca of mice given
mAb RB6-8C5 or DSS for 3 d; in contrast, mice given DSS for
Figure 1. Gastrointestinal Colonization Levels of C3H/HeN Mice Fed C.
albicans Strains SC5314 and CAF2–1
Mice were maintained on sterile water with 2 mg streptomycin/ml and
1,500 U penicillin G/ml throughout the duration of the experiment, and
0.2 mg gentamicin/ml was added once colonization was confirmed.
Points represent results from individual animals, and horizontal lines
represent the medians. n ¼ 16 for each strain.
doi:10.1371/journal.ppat.0040035.g001
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Author Summary
Candida albicans is a fungus that lives harmlessly in the gastro-
intestinal (GI) tracts of humans. In cancer patients and patients
undergoing bone marrow transplantation, however, the anti-cancer
drugs that are administered to these patients also cause the
undesired effect of suppressing the human immune system. The
treatments allow C. albicans to spread into the blood and other
organs and cause a severe disease. We found we could colonize the
GI tracts of mice with C. albicans and then suppress the immune
system with anti-cancer drugs to determine which components of
the innate immune system (neutrophils, lymphocytes, macrophages,
or GI tract integrity) are critical for preventing C. albicans from
speading from the GI tract. We found that lowering the neutrophil
counts and damaging the GI tract were both needed to cause
systemic infection with C. albicans. We also found that the ability of
C. albicans to switch from the yeast (spherical) form to the
filamentous form is also important for establishing invasive disease.
Our study provides new insights into the process of how a typically
harmless microorganism inhabiting the GI tract can cause severe
invasive disease once critical components of the host immune
system are compromised.7 d had ulcerations and focal areas of inﬂammation noted in
the cecum (Figure 2). The cecums of the mice that had
received DSS for 7 d and one dose of mAb RB6-8C5 showed
diffuse autolysis and sloughing. Mice given DSS alone showed
no evidence of C. albicans dissemination (Group 15); however,
when both DSS (2.5%) and mAb RB6-8C5 were given,
disseminated disease and mortality was achieved (50% to
87.5% mortality). Increasing the DSS concentration from
2.5% (Group 16) to 5% (Group 17) while still giving a single
200 lg/mouse dose of mAb RB6-8C5 achieved 100% mortality
associated with fungal dissemination to the liver.
When mice were found moribund or died, the levels of C.
albicans in the livers were comparable among animals given
the different treatment regimens when both neutropenia and
mucosal damage were induced (Figure 3). With the exception
of the four mice noted previously in Group 7 (mAb33), there
was no evidence of concurrent bacterial infection.
Translocation Studies
We analyzed the effects of immunosuppression and/or
mucosal damage treatments on translocation of C. albicans
from the GI tract. All mice in these studies were colonized
with C. albicans SC5314 and had levels of GI colonization
comparable to that shown in Figure 1 (data not shown). Mice
given no immunosuppression (Group A) all survived, and
none appeared moribund and none grew C. albicans from the
blood, spleen or MLN. Of note, fungi were found at very low
levels in the livers of 4 (out of 20) healthy-appearing mice (9,
42, 208, and 369 cfu/g). The mice given mAb RB6-8C5
treatment only (Group B) all survived, and none appeared
moribund. Similar to Group A, C. albicans was not found in
the blood, spleen or MLN of mice only given the neutropenia-
inducing mAb, but fungi were occasionally found in the liver
(5 out of 20; median 9.88 3 10
2 cfu/g, ﬁrst quartile ¼ 4.09 3
10
2, third quartile¼2.68310
3); these are clearly higher levels
than those found in the livers of mice in Group A which did
not receive any immunosuppression. In contrast, 3 of the 4
mice from the group given neutropenia-inducing mAb RB6-
8C5 plus MTX (Group C) died by day 4 post-immunosup-
pression, and 4 of 4 of these mice had died by day 5. All of
these mice showed signiﬁcant levels of C. albicans in the liver
(median 8.77 3 10
3 cfu/g, ﬁrst quartile ¼ 3.45 3 10
3, third
quartile ¼2.51 310
4). Finally, the mice given Cy only (Group
D) all had C. albicans in the liver by days 4 and 5: (median 7.71
3 10
4 cfu/g, ﬁrst quartile ¼ 3.87 3 10
4, third quartile ¼ 1.13 3
10
5).
C. albicans Morphogenesis as a Virulence Determinant
In order to assess the role of fungal morphogenesis as a
virulence determinant in our murine model, we tested three
C. albicans strains for their ability to colonize and disseminate
following immunosuppression: strain CAF2–1 is a wild-type
organism that was chosen because it, like the additional
mutants we tested, only has one copy of the URA3 gene [21];
strain HLC54 (cph1/cph1 efg1/egf1 exhibits decreased ﬁlament
formation, hereafter referred as Defg1/cph1 [22]; and strain
BCa-210 (tup1/tup1, hereafter referred to as Dtup1) exhibits
constitutive ﬁlamentous growth [23]. As shown in Figure 4,
both CAF2–1 (median¼2.99310
7 cfu/g, ﬁrst quartile¼2.383
10
7, third quartile¼3.30310
7) and strain Defg1/cph1 (median
¼ 5.32 3 10
7 cfu/g, ﬁrst quartile ¼ 4.69 3 10
7, third quartile ¼
1.03 3 10
8)w e r ea b l et oc o l o n i z et h eG Im u c o s aa t
comparable levels, while the Dtup1 strain colonized at a level
2-logs lower (median ¼ 7.71 3 10
4 cfu/g, ﬁrst quartile ¼ 5.0 3
10
4, third quartile 1.66310
6, p¼0.0003 by Mann Whitney test
compared with other two strains). This discrepancy is
explained by the fact that the maximum concentration
achievable of Dtup1 in water was approximately 2-logs lower
than the levels for the wild-type and Defg1/cph1 strains—a
difference which was consistent throughout the experiment.
Interestingly, strain Defg1/cph1 caused less mortality compared
to wild-type C. albicans (8 of 16 mice given Defg1/cph1 died
versus 14 of 16 mice infected with wild-type, p¼0.02, Fisher’s
exact test), whereas in spite of the 2-log lower levels of strain
Dtup1 in feces it caused mortality comparable to that of wild-
type (7 of 8 mice died; Figure 5). In preliminary experiments
with wild-type C. albicans strains SC5314 and CAF2–1, if we
administered immunosuppression (e.g., mAb RB6-8C5 plus
MTX) before ﬁnal levels of GI colonization (between 10
7 and
10
8 cfu/g) had been established, dissemination was not
induced, and all mice survived (data not shown). All of these
surviving mice continued to be colonized with their respec-
tive strains of C. albicans at levels comparable to that achieved
before administration of mAb and MTX.
Eight additional mice were administered higher concen-
trations of Dtup1 (5.5310
5 cfu/ml) in the drinking water, and
GI colonization levels achieved with this higher dose were
comparable to those of the wild-type C. albicans strain
(median ¼ 1.48 3 10
7 cfu/g, ﬁrst quartile ¼ 5.20 3 10
6, third
quartile ¼ 4.08 3 10
7), indicating that the level of GI
colonization can be increased for this strain. To determine
if this constitutively ﬁlamentous strain could by itself induce
mucosal damage sufﬁcient to achieve dissemination, we
Table 1. Immuosuppressive Regimens
Agent Dose Route of Administration Frequency Vendor Reference
CL2MBP (lipsomal clodronate) 200 ll (2 mg) IP Once Roche Diagnostics,
Mannheim Germany
[61]
Cyclophosphamide (Cy) 150 mg/kg/dose IP Three times
every other day
Sigma-Aldrich [63]
Dextran sulfate sodium (DSS) 2.5% or 5% (wt/vol)
in sterile water
Oral (via drinking water) 7 d Sigma-Aldrich [52,53]
Methotrexate (MTX) 150 mg/kg/dose IP Once Bedford Labs, Bedford, OH [29]
RB6-8C5 monoclonal antibody (mAb) 200 lg IP Once — [64]
doi:10.1371/journal.ppat.0040035.t001
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enhanced mucosal disruption sufﬁcient to allow fungal
dissemination in most mice was achieved by constitutive
hyphal expression, as 7 of 8 colonized mice made only
neutropenic still survived.
Discussion
In this study, we attempted to devise a mouse model to
study C. albicans pathogenesis and host factors leading to
susceptibility to disseminated infection that emulate the
pathophysiology that takes place in a human host, wherein
receipt of broad-spectrum antibiotics, extensive hospital-
ization, or administration of immunosuppressive agents
makes patients more vulnerable to invasive disease, often
associated with intercurrent mucosal disruption owing to
surgery, tumor invasion, or chemotherapy [24,25]. In neu-
tropenic patients, the role of the gut as a source for
disseminated candidiasis has been supported from autopsy
studies [26].
Several murine models of GI-derived C. albicans fungemia
and sepsis have been reported previously [27–32]. The levels
of GI colonization we obtained were substantially higher than
those achieved by prior investigators (1 to 3 log-fold higher)
[31,33] and were maintained at least up to 21 d (our latest
veriﬁcation date). This higher colonization level is most likely
due to the addition of penicillin to the drinking water.
Penicillin most likely led to reductions of endogenous
anaerobic bacterial ﬂora, promoting subsequent intestinal
overgrowth by C. albicans [34]. One other model did achieve
comparable colonization levels by also administering adjunc-
tive oral antibiotics [32]. The need for reduction of
indigenous ﬂora, particularly gram-negative bacteria, is
critical given that bacteria are just as likely as the C. albicans
to translocate and disseminate when immunosuppression is
administered [35].
We were able to show this model recapitulates important
aspects of human susceptibility to candidiasis, although there
are some limitations to consider. The model was developed
using adolescent/young adult 6- to 8-wk-old female C3H/HeN
mice, and its applicability to other mouse strains or mice of
other ages is not fully known. It would be difﬁcult to use
neonatal or infant mice in this model as others have done
with acute C. albicans infections [28–30] due to the need for
the animals to be able to drink both antibiotic water and
fungi in the water and then give the immunosuppressive/
mucosal disrupting agents, which would not be feasible with
mice prior to weaning. C3H/HeN mice were used because of
experience in a previous model of P. aeruginosa GI coloniza-
tion and neutropenia-induced dissemination [35], and the
fact that this strain has no major underlying immune deﬁcit
and is highly susceptible to DSS-induced colitis [36]. While we
have not extensively studied other mouse strains, initial
studies using Swiss Webster and C57/BL mice showed that
comparable levels of GI colonization, mortality, and liver
dissemination can be achieved when using Cy as the
immunosuppressive/mucosal damaging agent (AYK and
GBP, unpublished data). C. albicans administration via drink-
ing water limits the ability to control the infecting dose as
might be achieved by administering fungal cells by gavage.
However, administering C. albicans in the drinking water for 5
d led to a reproducible and consistent GI colonization level
(Figure 1) associated with dissemination following the
disruption of speciﬁc host defenses. Additionally, we did
not conﬁrm the entire spectrum of bacterial decontamina-
tion achieved by the antibiotics, as we did not utilize
anaerobic culture conditions or media speciﬁc for all types
of aerobic and anaerobic ﬂora. Therefore, we cannot be
absolutely sure that we truly eradicated all indigenous aerobic
and anaerobic ﬂora. In any case, whatever residual aerobic or
anaerobic ﬂora that remained after antibiotic decontamina-
tion does not appear to have any pathogenic signiﬁcance, as
evidenced by the fact that mice given only antibiotic
contamination and subsequent immunosuppression all ap-
peared healthy and exhibited 0% mortality.
We also chose to measure fungal levels in livers as an
indicator of dissemination. In other murine models of
intravenous C. albicans infection fungal levels in the kidneys
were used to conﬁrm systemic infection was achieved. In
preliminary experiments, we found that in mice that were
colonized with C. albicans, given subsequent immunosuppres-
sion (cyclophosphamide or RB6-8C5 þ MTX), and had no
other detectable infectious cause of death (e.g. bacterial
dissemination) that the liver (presence of C. albicans in 100%
of livers from deceased mice) was a more reliable organ for
conﬁrmation of dissemination compared to the kidneys
Table 2. Survival of Mice after Administration of Immunosuppressive Regimens
C. albicans
Strain
None Cy Cy þ MTX MTX mAb þ MTX mAb 3 1 mAb 3 3 Liposomal
Clodronate
Clodronate
þ mAb
Clodronate
þ DSS
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10
None — 8/8 8/8 8/8 7/8 8/8 8/8 8/8 8/8 8/8
SC5314 8/8 0/8 0/8 5/8 0/8 8/8 4/8
b 8/8 8/8 8/8
(p ¼ .00008)
a (p ¼ 0.00008)
a (p ¼ 0.10)
a (p ¼ 0.0007)
a
CAF2–1 8/8 0/8 4/8 2/8 8/8 5/8
b 8/8 8/8 8/8
(p ¼ 0.00008)
a (p ¼ 0.038)
a (p ¼ 0.020)
a
Abbreviations: mAb, RBC-8C5 monoclonal antibody; Cy, cyclophosphamide; MTX, methotrexate; DSS, dextran sulfate sodium; RAG
 / , recombinase activating gene deficient mice.
Mice were observed for a total of 7 days after the administration of immunosuppression, with the exception of Group 5, which was observed for periods of 5 days after each RB6-8C5 mAb
dose for a total of 15 days.
ap-value by Fisher’s exact test compared to untreated group.
bBacterial (Enterobacter spp.) dissemination only.
doi:10.1371/journal.ppat.0040035.t002
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Immune Deficits Needed for C. albicans Disease(presence of C. albicans in 50%–80% of kidneys in deceased
mice; AYK and GBP, unpublished data). One other model
using C. albicans GI colonization and chemotherapy-induced
dissemination also noted 100% recovery from the livers but
signiﬁcantly less recovery from the kidneys [32]. Finally, for
practical purposes we had to use organs for CFU enumera-
tion from moribund then euthanized mice or mice that died
between observations whose carcasses were frozen as close to
the time of death as feasible. However, in limited studies we
did compare the C. albicans yields from organs resected after
freezing and storage with yields from organs resected from
freshly euthanized mice and found the differences in CFU
were not statistically different (AYK and GBP, unpublished
data). Nonetheless, because there could be effects from post-
mortem fungal growth or losses upon storage at  208C one
must be cautious in using levels of C. albicans in the organs as a
measure of virulence.
We also attempted to determine how C. albicans might
spread from the GI lumen to internal organs. Given the
sporadic and low levels of hepatic dissemination in mice
Table 2. Extended.
RAG
 /  RAG
 / 
þ mAb
RAG
 / 
þ 2.5% DSS
RAG
 / 
þ Clodronate
DSS (2.5%, 5%)
(,8 days)
2.5% DSS
þ mAb
5% DSS
þ mAb
Group 11 Group 12 Group 13 Group 14 Group 15 Group 16 Group 17
———
— 8/8 8/8 8/8
8/8 4/4 4/4 4/4 8/8 1/8 0/8
(p ¼ 0.0007)
a (p ¼ 0.00008)
a
8/8 4/4 4/4 4/4 8/8 4/8 0/8
(p ¼ 0.038)
a (p ¼ 0.00008)
a
Figure 2. DSS-Induced Murine Gastrointestinal Mucosal Damage
Histological sections of cecums from mice colonized with C. albicans strain SC5314 with continuation of penicillin, streptomycin, and gentamicin in the
drinking water then given water with 2.5% DSS for various periods with or without induction of neutropenia.
(A) No DSS, 200 lg of RB6-8C5 IP once.
(B) DSS for 3 d.
(C) DSS for 7 d.
(D) DSS for 7 d and after the third day of DSS mice were given 200 lg of RB6-8C5 IP once and observed for 96 h after the RB6-8C5 dose. Magnification:
Objective 103.
Sections in (A) and (B) have normal histologic appearance, whereas in panels (C) and (D) disruption of the epithelial barrier integrity was clearly seen.
doi:10.1371/journal.ppat.0040035.g002
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Immune Deficits Needed for C. albicans Diseasecolonized with C. albicans but not receiving any immunosup-
pression, it is conceivable that C. albicans is able to translocate
to the liver via the portal circulation or via the biliary tree in
the absence of immunosuppression, but does not cause
widespread disease because of a competent immune system
that is able to prevent signiﬁcant dissemination of the fungi.
In our study, mice colonized with C. albicans and given only
RB6-8C5 mAb also showed sporadic levels of hepatic
dissemination, albeit at higher levels than in mice that did
not receive immunosuppression. The higher fungal burden is
most likely secondary to the lack of neutrophils and thus the
subsequent diminished ability of the immunosuppressed
animal to clear the C. albicans from the liver. But even in
the absence of neutrophils, the fungal burden was not enough
to cause frequent morbidity or death. Not surprisingly, when
we administered systemic chemotherapeutic agents such as
cyclophosphamide (resulting in both neutropenia and GI
mucosal damage) we were able to reproducibly achieve
widespread dissemination with C. albicans.
In the ﬁnal analysis we found both neutropenia and
disruption of the integrity of the GI mucosa were needed
for fungal dissemination. In several intravenous murine
models of C. albicans systemic infection, neutrophil depletion
notably increases fungal burden and mortality [37,38]. In this
murine model, however, neutropenia alone is not sufﬁcient
for extra-intestinal dissemination most likely due to the fact
that C. albicans is still unable to breach the intact GI
epithelium.
Although one prior study implicated the importance of
CD4þ lymphocytes in protective immunity to systemic C.
albicans infection [39], several studies in SCID mice have
shown that a defect in the TH1 CD4þ T-cell response to C.
albicans results in mucosal or esophageal candidiasis but not
in systemic dissemination. Even in C5 deﬁcient DBA/2 mice
[38] and a recent murine HIV model [40], T cell depletion also
does not result in disseminated C. albicans disease. Although
the RB6-8C5 mAb at the dose used also induces some
depletion of lymphocytes [35], we found that both C3H/
HeN and RAG
 / mice that lack mature lymphocytes were not
susceptible to fungal disease following GI colonization and
neutropenia alone. Thus, our murine model correlates with
these previous studies: lymphopenia alone or in combination
with macrophage depletion, neutrophil depletion, or GI
mucosal disruption without neutropenia did not result in
fungal dissemination or death of the colonized mouse.
Similarly, depleting macrophages only did not lead to any
susceptibility to systemic fungal infection. Although murine
peritoneal macrophages [41,42], pulmonary alveolar macro-
phages [43], Kuppfer’s cells [44] and human peripheral blood
monocytes [45] have the ability to phagocytose and kill C.
albicans in vitro, in vivo studies on disseminated candidiasis
have generated evidence both supporting [42,46–48] and
refuting the importance [49–51] of macrophages. Of the two
studies utilizing selective macrophage depletion [48,50], only
one administered liposomal clodronate followed by intra-
venous fungal injection to produce a disseminated candidia-
sis. Spleens from the mice treated with clodronate lost their
ability to trap yeast [48]. Furthermore, when macrophage-
depleted mice were systemically challenged with C. albicans,
not only was clearance of yeast decreased in blood, but
kidneys had higher fungal burdens and overall mouse survival
was decreased. Although we used the same dose of clodro-
nate, we also utilized FACS analysis to quantify the macro-
phage depletion (37% depletion) rather than measuring
peripheral blood monocyte counts (30%–85% depletion).
Ultimately, our lack of ﬁnding a signiﬁcant role for macro-
phages in host resistance to C. albicans may be related to the
use of different models. In an intravenous model with direct
Figure 3. Viable Counts of C. albicans Strains SC5314 or CAF2–1 in the
Livers of Deceased C3H/HeN Mice that Were Previously Colonized in the
GI Tract with C. albicans and Subsequently Given Various Forms of
Immunosuppression
Cy, cyclophosphamide; MTX, methotrexate; RB6, RB6-8C5 mAb; DSS,
dextran sulfate sodium. Points represent results from individual animals.
Horizontal lines with bars represent median with interquartile range
when n . 3, otherwise only the median is shown.
doi:10.1371/journal.ppat.0040035.g003
Figure 4. Gastrointestinal Colonization Levels of Female 6- to 8-Wk-Old
C3H/HeN Mice Fed C. albicans Strains CAF2–1, HLC-54 (Defg1/cph1), and
BCa-210 (Dtup1)
Points represent results from individual animals, and horizontal lines
represent the medians. n¼8 for CAF2–1, n¼7 for Defg1/cph1 and Dtup1.
Colonization levels with strain Dtup1 were significantly lower (p¼0.0003
by Mann Whitney test) compared with other two strains.
doi:10.1371/journal.ppat.0040035.g004
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enough of a deﬁcit to lead to more severe disseminated
disease. In our murine model, it may be that macrophages do
play a role, but more substantial macrophage depletion may
be necessary to see this effect.
Finally, while DSS has been used for experimental murine
models of human inﬂammatory bowel disease [52,53], the
histopathologic damage induced by DSS has some similarities
to chemotherapy-induced mucositis in that both result in
denudation and ulceration. Interestingly, when we main-
tained the same degree of neutropenia but increased the GI
mucosal damage (by changing DSS from 2.5% to 5%), we
notably increased the mortality to 100%, and this is most
likely secondary to the increased mucosal damage caused by
the higher concentration of DSS. These studies further
support our hypothesis that it is a combination of neutrope-
nia and GI mucosal damage that are critical for C. albicans
dissemination in our murine model.
In the host, C. albicans grows as all known morphologic
forms (budding yeast, pseudohyphal ﬁlaments, and true
hyphae), and it has been postulated that the ability to induce
hyphal formation is a critical virulence determinant [22].
Mutant strains of C. albicans that are incapable of hyphal
formation have been found to be avirulent in murine models
of disseminated candidiasis [54–56]. Whether it is simply that
hyphae formation leads to an increased ability to invade host
epithelial cells, or induces greater cytotoxicity, or whether the
advantage of ﬁlamentous growth is in providing greater
resistance to phagocytosis [22], the deﬁnitive mechanistic
explanation linking hyphal formation to virulence is lacking.
When testing the morphogenesis mutants, Defg1/cph1, which
exhibit decreased ﬁlament formation [22], and Dtup1, which
exhibits constitutive ﬁlamentous growth [23], we noted a
nearly 2-log lower GI colonization level of the Dtup1 mutant
compared to the wild-type strain, CAF2–1. As noted earlier,
this discrepancy in colonization level was most likely due to
the difﬁculty of suspending Dtup1 in drinking water and
achieving higher concentrations. All of the mice colonized
with strain Dtup1 had colonization levels lower than the 10
7 to
10
8 cfu/g achieved with C. albicans strains SC5314 and CAF2–1,
yet 7 of the 8 mice colonized with the Dtup1 strain died
following immunosuppression and GI mucosal damage. Since
it is difﬁcult to titrate inocula in our murine model, this
ﬁnding of dissemination and mortality in the setting of
signiﬁcantly lower GI colonization levels may suggest that the
Dtup1 mutant is more virulent in this setting. The appropriate
quantiﬁcation of ﬁlamentous strains, however, is confounded
by the fact that cells may not be properly separated, and thus
CFUs are underestimated. In addition, ﬁlamentous strains
such as Dtup1 may adhere to the GI mucosa more tenaciously,
and thus levels in the stool could be an underestimation of
actual GI colonization levels. However, increased ﬁlamentous
growth of the Dtup1 mutant alone is not sufﬁcient to disrupt
the GI mucosa and allow for fungal dissemination even in the
setting of neutropenia.
Our ﬁndings with CAF2–1 and Defg1/cph1were consistent
with previous investigators that utilized an intravenous model
of C. albicans dissemination [22,57,58]. However, in a model of
hypoxic-induced GI translocation [59] and another study
using oral inoculation followed by intraperitoneal (IP)
injections of dexamethasone for immunosuppression [57],
Defg1/cph1 was found to be more invasive compared to the
wild-type CAF2–1. Whereas both of these studies used the
presence of C. albicans in extraintestinal organs to deﬁne
invasiveness or virulence, we used death attributable to C.
albicans dissemination. Furthermore, we utilized a different
means of immunosuppression and attempted to verify that
bacterial translocation was not a confounding factor. There-
fore, our ﬁndings with Defg1/cph1 support the hypothesis that
the ability to form ﬁlaments is important for translocation
and dissemination with C. albicans.
In conclusion, we have developed a murine model of C.
albicans GI colonization following anti-microbial agent re-
ductions in the indigenous ﬂora and systemic spread during
neutropenia that additionally requires GI mucosal damage.
Neutropenia alone is not sufﬁcient to produce disseminated
C. albicans disease in this murine model. Being able to control
these host factors should allow for a more detailed study of
host and fungal factors needed to achieve GI colonization and
systemic dissemination. These factors should thus be useful
for evaluating pathogenesis as well as therapies to control C.
albicans invasive infections.
Materials and Methods
Fungal strains and growth. The strains of C. albicans used are listed
in Table 3. C. albicans strains were grown overnight at 378C in yeast
extract-peptone-dextrose (YPD) broth, harvested by centrifugation,
washed with PBS, and resuspended in PBS. C. albicans concentration
was determined by use of a hemocytometer.
Murine model of antibiotic-induced GI tract colonization by C.
albicans and immunosuppressive-induced fungemia. Six- to 8-wk-old
female C3H/HeN mice (Harlan, http://www.harlan.com/models/c3h.
asp) were housed as groups of 4 in sterilized cages equipped with
ﬁlter hoods. In some experiments, 6-wk-old female recombinase
activating gene deﬁcient mice (Rag
 /
 , http://jaxmice.jax.org/strain/
002216.html) were used. Mice were supplied with sterile bedding,
sterile water and sterile mouse chow and maintained under speciﬁc
pathogen-free conditions at the ARCM-MCP animal facility at
Harvard Medical School in compliance with the Harvard Medical
Area Institutional Animal Care and Use Committee guidelines. To
deplete the indigenous GI bacterial and fungal ﬂora, mice were fed
sterile water with 2 mg streptomycin/ml (Research Product Interna-
tional, Mt. Prospect, IL), 1500 U penicillin G/ml (Sigma-Aldrich, St.
Louis, MO), and 0.250 mg ﬂuconazole/ml (Roxanne Laboratories,
Columbus, OH) for 3 d, then switched to the same concentrations of
streptomycin and penicillin G in their drinking water for one more
Figure 5. Survival Curve of C3H/HeN Mice Fed C. albicans Strains CAF2–1,
HLC-54 (Defg1/cph1), or BCa-210 (Dtup1) and Subsequently Given mAb
RB6-8C5 (200 lg IP) and Methotrexate (150 mg/kg/dose IP)
Median survival of mice colonized with strain Defg1/cph1 was
significantly higher than that of mice colonized with wild-type C.
albicans CAF2–1 (p ¼ 0.01, log rank test). Each group contained 8 mice.
doi:10.1371/journal.ppat.0040035.g005
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Immune Deficits Needed for C. albicans Diseaseday. Stool was collected from individual mice (0.030–0.050 g per stool
pellet), homogenized in 1 ml 1% protease peptone, and 100 ll of the
homogenate was spread and plated on yeast extract-peptone-
dextrose (YPD), trypticase soy (TSA), or MacConkey agars to verify
reduction of the targeted indigenous GI microbial ﬂora. C. albicans
strains (grown as described above) were added to sterile water with
2 mg streptomycin/ml, and 1,500 U penicillin G/ml at approximately
107 cfu/ml, and then C. albicans was administered via the drinking
water to mice for 5 d. Candidal levels were constant in the drinking
water and therefore water bottles were not changed during this time.
After 5 d of exposure to Candida, stool was again collected,
homogenized in 1 ml 1% protease peptone, serially diluted and
plated on YPD agar with 0.010 mg vancomycin/ml and 0.100 mg
gentamicin/ml to measure levels of GI colonization by C. albicans.W e
then induced immunosuppression by treating the mice with the
immunosuppressive agents listed in Table 1. After administration of
immunosuppressive agents, mice were fed sterile water with 2 mg
streptomycin/ml, 1,500 U penicillin G/ml, and 0.2 mg gentamicin/ml
for the remainder of the experiment and monitored for morbidity
for 7 d. Moribund mice were euthanized and along with mice found
dead between observation periods, the carcasses were frozen at minus
208C, later thawed, livers resected, homogenized in 1 ml 1% protease
peptone, serially diluted and 100 ll of the homogenate was spread-
plated on YPD with 0.100 mg gentamicin/ml (Research Product
International, Mt. Prospect, IL) and 0.010 mg vancomycin/ml (Sigma-
Aldrich), and additional 100 ll amounts plated onto TSA and
MacConkey agar plates. Growth media were incubated at 378C
overnight under aerobic conditions. The presence of a homogeneous
population of creamy-white colonies on YPD with gentamicin and
vancomycin was used for conﬁrmation of C. albicans systemic
dissemination (Figure 6).
Production or RB6-8C5 monoclonal antibody and induction of
neutropenia. The RB6-8C5 monoclonal antibody (mAb) speciﬁc for
the Ly6 antigen highly expressed by polymorphonuclear neutrophils
(PMN) was produced by growth of hybridoma cells in culture
(Dulbecco’s modiﬁed Eagle’s medium with 10% fetal calf serum
[FCS]) followed by puriﬁcation of antibody by afﬁnity chromatog-
raphy, as previously described [35]. A single dose of 200 lg of RB6-
8C5 was administered to C3H/HeN mice to produce a severe
neutropenia (absolute neutrophil count , 100/mm
3) for 5 d [35].
In vivo macrophage depletion. CL2MBP (clodronate) was a gift
from Roche Diagnostics (Mannheim, Germany). Preparation of
liposomes containing CL2MBP was done as described previously
[60]. For assessment of macrophage depletion, three uninfected mice
per group were inoculated IP with 200 ll of PBS liposomes or with
CL2MBP liposomes (2 mg) [61]. At 2 d later, macrophages were
quantiﬁed in the bone marrow and spleens using FACS analysis. Bone
marrow and spleens were harvested from euthanized mice. To
prepare single cell suspensions, spleens were sliced into small pieces
with a scalpel, and the pieces placed at the ends of autoclaved frosted-
glass microscope slides (Fisher Scientiﬁc, Pittsburgh, PA), previously
immersed in Hank’s balanced salt solution (HBSS; Gibco/Invitrogen,
Carlsbad, CA) with 10% FCS. Splenic fragments were disrupted by
opposing the slide ends and applying gentle pressure in round
circular movements. The resulting splenic cell suspension was
collected in a Petri dish and ﬁnally run over a 70 lm nylon cell
strainer (BD Biosciences, San Diego, CA). For bone marrow cells,
single cell suspensions were prepared by running bone marrow cells
resuspended in HBSS with 10% FCS over a 70 lm nylon cell strainer.
Cells from the three mice were pooled. Erythrocytes were eliminated
using lysing solution (BD Biosciences, San Diego, CA). The remaining
hematopoetic cells were washed and resuspended in PBS supple-
mented with 2% FCS, 1% bovine serum albumin, and 0.1% NaN3
(FACS buffer). Cells were blocked with Mouse Fc Block (BD
Biosciences, San Diego, CA) at 1 lg per 10
6 cells for 5 minutes at
48C. Alexa-488-conjugated antibody to the mouse macrophage cell
surface glycoprotein F4/80 (mAb BM8, Caltag/Invitrogen, Carlsbad,
CA) and/or phycoerythrin-conjugated antibody to mouse CD11b (BD
Biosciences, San Diego, CA) at 10 lg/ml/test were added to 1 3 10
6
cells in 100 ll of FACS buffer then incubated at 48C for 30 min
followed by washing with FACS buffer. To determine background
levels of ﬂuorescence, non-antigen speciﬁc isotype controls (Alexa-
488-conjugated-IgG2a or phycoerythrin-conjugated-IgG2b antibodies)
were used as primary antibodies. After staining, cells were ﬁxed with
1% paraformaldehyde. Fluorescence was detected on a Dako MoFlo
High Performance Cell Sorter (Dako, Fort Collins, CO), and data
analysis was performed using Summit Software v 4.3 (Dako, Fort
Collins, CO). Gates were set to include CD11b and F4/80 double
positive cells.
Livers and spleens from mice inoculated IP with 200 ll of PBS
liposomes or CL2MBP liposomes (2 mg) 48 h prior to sacriﬁce were
resected, ﬁxed in Bouin’s solution, and parafﬁn-embedded sections
cut and mounted on slides. 5 lm sections of hepatic and splenic tissue
were deparafﬁnized in xylene and rehydrated in a series of reverse
ethanol washes (100%, 95%, and 80% ethanol sequentially). The
samples were then blocked by incubation in histology blocking buffer
(PBS containing 1% bovine serum albumin and 2% normal rat serum
[Sigma-Aldrich]) for 15 min at 378C. Samples were then incubated
with 1 lg Alexa-488-conjugated antibody to the macrophage F4/80
antigen/ml for 90 min at 378C. To detect background ﬂuorescence, an
appropriate isotype control antibody (1 lg rat IgG2a/ml) was used.
The samples were then washed and sections visualized with the 103
alpha-plan lens on a Zeiss Axioplan 2 microscope, ﬁtted with ﬁlter
sets for GFP ﬂuorescence, and a cooled CCD Hamamatsu Orca
camera. Images were acquired and processed using MetaMorph
(Molecular Devices Corporation, Sunnyvale, CA) and Adobe Photo-
shop software [62].
In vivo gastrointestinal mucosal disruption. To verify we had
induced GI mucosal damage/disruption with dextran sodium sulfate
(DSS), C3H/HeN mice (6- to 8-wk-old females) colonized with C.
albicans strain SC5314 and maintained on sterile water with
streptomycin, penicillin, and gentamicin to prevent bacterial
recontamination were divided into four groups and sacriﬁced for
cecal histology after the following speciﬁc treatments: Group A was
given RB6-8C5 mAb once; Group B was given 5% DSS for 3 d; Group
C was given 5% DSS for 7 d; and Group D was given 5% DSS water
for 7 d, and after the third day of DSS water, mice were given mAb
RB6-8C5 once, and observed for 96 h after the RB6-8C5 dose. Ceca
were resected and immediately ﬁxed in Bouin’s solution. Sections
w e r es t a i n e dw i t hh e m a t o x y l i na n de o s i na n dr e v i e w e db ya
veterinary pathologist.
Translocation studies. To determine if the C. albicans colonizing the
GI tract was translocating to extra-gastrointestinal sites, mice were
colonized with C. albicans strain SC5314 using the protocol described
above then organized into the following four groups containing 24
Table 3. Fungal Strains Used in This Study
Strain Description Reference
SC5314 Wild-type strain [21]
CAF2–1 Wild-type strain [21]
HLC-54 cph1/cph1 efg1/egf1 (Dcph1/efg1) [22]
BCa-210 tup1/tup1 (Dtup1) [23]
doi:10.1371/journal.ppat.0040035.t003
Figure 6. Schema for Murine Model of C. albicans Gastrointestinal
Colonization and Dissemination after Administration of Immunosup-
pression
doi:10.1371/journal.ppat.0040035.g006
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Immune Deficits Needed for C. albicans Diseasemice per group: Group A, no immunosuppression; Group B,
neutropenia induced by IP injection of 200 lg RB6-8C5 mAb once;
Group C, neutropenia and GI mucosal disruption induced by one IP
injection of 200 lg RB6-8C5 mAb and a contemporary, single IP
injection of 150 mg/kg MTX; and Group D, neutropenia and mucosal
damage induced by three IP injections of 150 mg/kg Cy given every
other day (Table 4). Four mice from each group were sacriﬁced on
days 0, 1, 2, 3, 4, and 5 after immunosuppression was initiated. Blood
(100 ll) was drawn from an ethanol-cleaned tail vein and spread-
plated onto YPD agar with vancomycin and gentamicin, TSA, and
MacConkey agar plates. Mice were then sacriﬁced. Mesenteric lymph
nodes (MLN), spleens, and livers were immediately resected; organs
were homogenized in 1 ml of 1% protease peptone; and 100 llo f
homogenate was spread-plated on YPD agar with vancomycin and
gentamicin, TSA, and MacConkey agar plates. The presence of a
homogeneous population of creamy-white colonies on YPD with
gentamicin and vancomycin were used for conﬁrmation of the
presence of C. albicans. Serial dilutions and plating for fungal
enumeration were also done to obtain quantitative data (CFU per
gram tissue and CFU per ml blood).
Statistical analyses. Survival data were analyzed by Fisher’s exact
test and the survival curve was analyzed by the Kaplan-Meier log rank
test using the GraphPad Prism software (San Diego, CA). Two-way
comparisons of GI colonization levels were carried out using the
Mann-Whitney tests and Prism software, and when multiple
comparisons or more than two groups were analyzed, Bonferroni’s
correction to the signiﬁcance level a was invoked.
Supporting Information
Figure S1. Immunohistochemical Staining with Alexa-488 Anti-
Mouse F4/80 of Murine Spleens and Liver after Liposomal Clodronate
Administration
(A) Isotype control (Alexa-488 rat IgG2a) staining of normal murine
spleen.
(B) Alexa-488 rat anti-mouse F4/80 staining of normal murine spleen.
(C) Isotype control (Alexa-488 rat IgG2a) staining of normal murine
spleen 48 h after IP clodronate.
(D) Alexa-488 rat anti-mouse F4/80 staining of murine spleen 48 h
after IP clodronate.
(E) Isotype control (Alexa-488 rat IgG2a) staining of normal murine
liver.
(F) Alexa-488 rat anti-mouse F4/80 staining of normal murine liver.
(G) Isotype control (Alexa-488 rat IgG2a) staining of normal murine
liver 48 h after IP clodronate.
(H) Alexa-488 rat anti-mouse F4/80 staining of murine liver 48 h after
IP clodronate. Magniﬁcation: Objective 103.
Found at doi:10.1371/journal.ppat.0040035.sg001 (3.9 MB TIF).
Figure S2. Expression of F4/80 and CD11b on Murine (C3H/HeN)
Bone Marrow and Spleen Cells
Alexa-488–conjugated antibody to the mouse macrophage cell
surface glycoprotein F4/80 and/or phycoerythrin-conjugated anti-
body to mouse CD11b were used. Cells from three mice were pooled
for each analysis.
(A) Bone marrow from normal mice.
(B) Bone marrow from mice treated with liposomal clodronate 200 ll
(2 mg) 48 h prior to analysis.
(C) Splenocytes from normal mice.
(D) Splenocytes from mice treated with liposomal clodronate 200 ll
(2 mg) 48 h prior.
Found at doi:10.1371/journal.ppat.0040035.sg002 (4.9 MB TIF).
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